Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.
The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...
The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...
Highlands Oncology's innovative remote monitoring model enhances cancer care, reducing ER visits and improving treatment ...
Final 5-year data from the phase 2 2102-HEM-101 trial (NCT02719574) show that olutasidenib (Rezlidhia) delivered sustained ...
This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...
This discussion provides an overview of current treatment standards and practical challenges in managing advanced gastric ...
This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...
The sandwich therapy showed a 2-year overall survival rate of 97% and a leukemia-free survival rate of 72% in Ph-negative ...
“This points more toward a model where the tumor is cleared and the T cells largely go away,” Hinrichs noted in the interview ...
Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, ...
1. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive-stage small-cell lung cancer. FDA. November 19, 2025. Accessed November 19, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback